RecruitingNot Applicable

Improve Cancer-related Cognitive Impairment

United States64 participantsStarted 2024-09-01

Plain-language summary

Cancer-related cognitive impairment (CRCI), also known as "chemobrain," is the cognitive decline that negatively impacts the majority of cancer patients undergoing chemotherapy, radiation, and/or hormonal treatments. This application focuses on evaluating if using a cognitive mobile training application can decrease the impact of CRCI in gynecologic oncology patients through a multidisciplinary approach with patients undergoing assessments by our neurocognitive team.

Who can participate

Age range18 Years – 90 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria are: * newly diagnosed gynecologic malignancy (uterine, cervical, ovarian, primary peritoneal, vulvar, or vaginal) and undergoing chemotherapy * own a smartphone or tablet with ability to download cognitive training application * and age \>21 years old Exclusion criteria include: * medical diagnosis of dementia * significant underlying mental diagnoses for which they are on more than 1 medication for (patients with depression or anxiety on single-agent therapy will be able to participate * age \<21

What they're measuring

Neurocognitive function

Timeframe: From initiation of chemotherapy through 2 years

Neurocognitive function

Timeframe: From initiation of chemotherapy through 2 years

Trial details

NCT IDNCT05864274

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-08-01

Contact for this trial

Teresa K Boitano, MD

2059344986 tlboitano@uabmc.edu

View on ClinicalTrials.gov More Gynecologic Cancer trials